

Literatura

- Adler NR, Wolfe R, Kelly JW, et al. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. *Br J Cancer*. 2017;117:1026–1035.
- Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncol*. 2019;20:378–389.
- Aoude LG, Gartside M, Johansson P, et al. Prevalence of germline BAP1, CDKN2A, and CDK4 mutations in an Australian population-based sample of cutaneous melanoma cases. *Twin Res Hum Genet*. 2015;18:126–33.
- Ascierto PA, Long GV, Robert C, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. *JAMA Oncol*. 2019;5:187–194.
- Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2016;17:1248–1260.
- Bafaloukos D, Gazouli I, Koutserimpas C, et al. Evolution and progress of mRNA vaccines in the treatment of melanoma: future prospects. *Vaccines (Basel)*. 2023;11:636.
- Bandarchi B, Jabbari CA, Vedadi A, et al. Molecular biology of normal melanocytes and melanoma cells. *J Clin Pathol*. 2013;66:644–648.
- Bardi GT, Smith MA, Hood JL. Melanoma exosomes promote mixed M1 and M2 macrophage polarization. *Cytokine*. 2018;105:63–72.
- Berwick M, Orlow I, Hummer AJ, et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. *Cancer Epidemiol Biomarkers Prev*. 2006;15:1520–1525.
- Boiko AD, Razorenova OV, Van De Rijn M, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. *Nature*. 2010;466:133–137.
- Bommareddy PK, Patel A, Hossain S, et al. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. *Am J Clin Dermatol*. 2017;18:1–15.

- Buyyounouski MK, Choyke PL, McKenney JK, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer. Eighth edition. *Cancer Staging Manual*. *CA Cancer J Clin*. 2017;67:245–253.
- Damsky WE, Bosenberg M. Melanocytic nevi and melanoma: Unraveling a complex relationship. *Oncogene*. 2017;36:5771–5792.
- Di Raimondo C, Lozzi F, Di Domenico PP, et al. The diagnosis and management of cutaneous metastases from melanoma. *Int J Mol Sci*. 2023;24:14535.
- Díez-Torre A, Andrade R, Eguizábal C, et al. Reprogramming of melanoma cells by embryonic microenvironments. *Int J Dev Biol*. 2009;53:1563–1568.
- Duffy K, Grossman D. The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. *J Am Acad Dermatol*. 2012;67:1–12.
- Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2018;19:1315–1327.
- Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2017;18:435–445.
- Dvořánková B, Szabo P, Lacina L, et al. Fibroblasts prepared from different types of malignant tumors stimulate expression of luminal marker keratin 8 in the EM-G3 breast cancer cell line. *Histochem Cell Biol*. 2012;137:679–685.
- Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EO-RTC 18071): A randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2015;16:522–530.
- Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. *Eur J Cancer*. 2019;119:1–10.
- Faries B, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. *N Engl J Med*. 2017;376:2211–2222.

- Fedorenko IV, Abel EV, Koomen JM, et al. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. *Oncogene*. 2016;35:1225–1235.
- Fedorenko IV, Wargo JA, Flaherty KT, et al. Therapeutic escape. 2016;135:3115–3124.
- Fedorenko IV, Wargo JA, Flaherty KT, et al. BRAF inhibition generates a host-tumor niche that mediates therapeutic escape. *J Invest Dermatol*. 2015;135:3115–3124.
- Fitzpatrick TB, Breathnach AS. The epidermal melanin unit system. *Dermatol Wochenschr*. 1963;147:1–9.
- Fujimura T, Kakizaki A, Kambayashi Y, et al. Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages. *Exp Dermatol*. 2018;27:64–70.
- Fujimura T, Kambayashi Y, Furudate S, et al. Receptor activator of nuclear factor kappa-B ligand (RANKL)/RANK signaling promotes cancer-related inflammation through M2 macrophages. *Exp Dermatol*. 2016;25:397–399.
- Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. *Eur J Cancer*. 2020;126:141–158.
- Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. *Eur J Cancer*. 2020;126:159–177.
- Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. *Nature*. 2017;545:495–499.
- Guo Y, Zhang X, Zeng W, et al. TRAF6 activates fibroblasts to cancer-associated fibroblasts (CAFs) through FGF19 in tumor microenvironment to benefit the malignant phenotype of melanoma cells. *J Invest Dermatol*. 2020;140:2268–2279.
- Gurzu S, Beleaua MA, Jung I. The role of tumor microenvironment in development and progression of malignant melanomas – A systematic review. *Rom J Morphol Embryol*. 2018;59:23–28.
- Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. *Lancet*. 2012;380:358–365.

- Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. *Nature*. 2017;545:175–180.
- Hearing VJ. Determination of melanin synthetic pathways. *J Invest Dermatol*. 2011;131:8–11.
- Hendrix MJC, Seftor EA, Seftor REB, et al. Reprogramming metastatic tumour cells with embryonic microenvironments. *Nat Rev Cancer*. 2007;7:246–55.
- Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. *Lancet*. 2016;387:1540–1550.
- Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2018;19:1480–1492.
- Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010;363:711–723.
- Holm-Schou ASS, Philipsen PA, Wulf HC. Skin cancer phototype: A new classification directly related to skin cancer and based on responses from 2869 individuals. *Photodermatol Photoimmunol Photomed*. 2019;35:116–123.
- Huang AC, Orłowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. *Nat Med*. 2019;25:454–461.
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*. 2011;364:2507–2516.
- Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAF V600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. *Ann Oncol*. 2017;28:2581–2587.
- Cho JH, Robinson JP, Arave RA, et al. AKT1 activation promotes development of melanoma metastases. *Cell Rep*. 2015;13(5).
- Jobe NP, Rösel D, Dvořánková B, et al. Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness. *Histochem Cell Biol*. 2016;146:205–217.
- Jobe NP, Živicová V, Mifková A, et al. Fibroblasts potentiate melanoma cells in vitro invasiveness induced by UV-irradiated keratinocytes. *Histochem Cell Biol*. 2018;149:503–516.
- Johansson J, Kiffin R, Andersson A, et al. Isolated limb perfusion with melphalan triggers immune activation in melanoma patients. *Front Oncol*. 2018;8:570.

- Kakadia S, Yarlagadda N, Awad R, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. *Onco Targets Ther.* 2018;11:7095–7107.
- Klemen ND, Feingold PL, Goff SL, et al. Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma. *Ann Surg Oncol.* 2017;24:135–141.
- Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in melanoma: recent advances and future directions. *Cancers (Basel).* 2023;15:1106.
- Kodet O, Dvořánková B, Bendlová B, et al. Microenvironment-driven resistance to B-Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblasts. *Int J Mol Med.* 2018;41:2687–2703.
- Kodet O, Kučera J, Strnadová K, et al. Cutaneous melanoma dissemination is dependent on the malignant cell properties and factors of intercellular crosstalk in the cancer microenvironment (Review). *Int J Oncol.* 2020;57:619–630.
- Kodet O, Krajsová I. Maligní melanom, incidence, rizikové faktory a jeho časná diagnostika. *Onkologie.* 2017;11:138–143.
- Kodet O, Lacina L, Krejčí E, et al. Melanoma cells influence the differentiation pattern of human epidermal keratinocytes. *Mol Cancer.* 2015;14:1.
- Koshenkov VP, Broucek J, Kaufman HL. Surgical management of melanoma. *Cancer Treat Res.* 2016;167:149–179.
- Kučera J, Dvořánková B, Smetana K, et al. Fibroblasts isolated from the malignant melanoma influence phenotype of normal human keratinocytes. *J Appl Biomed.* 2015;13:195–198.
- Lacina L, Kodet O, Dvořánková B, et al. Ecology of melanoma cell. *Histol Histo-pathol.* 2018;33:247–254.
- Lacina L, Plzak J, Kodet O, et al. Cancer microenvironment: What can we learn from the stem cell niche. *Int J Mol Sci.* 2015;16:24094–24110.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med.* 2019;381:1535–1546.
- LeBoit PE. The morphology of tumor progression in melanoma in situ. *Dermatol.* 2019;155:775–776.

- Liu T, Zhou L, Yang K, et al. The β -catenin/YAP signaling axis is a key regulator of melanoma-associated fibroblasts. *Signal Transduct Target Ther.* 2019;4:63.
- Li Z, Zhou J, Zhang J, et al. Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5. *Int J Cancer.* 2019;145:1946–1957.
- Long GV, Grob JJ, Nathan P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. *Lancet Oncol.* 2016;17:1743–1754.
- Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. *N Engl J Med.* 2017;377:1813–1823.
- Long GV, Lebbe C, Atkinson V, et al. The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i. *J Clin Oncol.* 2019;37(15 Suppl):9531–9531.
- Long GV, Saw RPM, Lo S, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. *Lancet Oncol.* 2019;20:961–971.
- Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Oncol.* 2018;19:510–520.
- Martinez-Rodriguez M, Thompson AK, Monteagudo C. High CCL27 immunoreactivity in “supratumoral” epidermis correlates with better prognosis in patients with cutaneous malignant melanoma. *J Clin Pathol.* 2017;70:15–19.
- Moreno A, Manrique-Silva E, Virós A, et al. Histologic features associated with an invasive component in lentigo maligna lesions. *JAMA Dermatology.* 2019;155:782–788.
- Muzumdar S, Argraves M, Kristjansson A, et al. A quantitative comparison between SOX10 and MART-1 immunostaining to detect melanocytic hyperplasia in chronically sun-damaged skin. *J Cutan Pathol.* 2018;45: 63–268.
- Nemeth K, Szabo S, Cottrell CE, et al. Mosaic pathogenic HRAS variant in a patient with nevus spilus with agminated Spitz nevi and parametrial-uterine rhabdomyosarcoma. *Br J Dermatol.* 2018;178:804–806.

- Němejcová K, Tichá I, Bártů M, et al. Comparison of five different scoring methods in the evaluation of inflammatory infiltration (tumor-infiltrating lymphocytes) in superficial spreading and nodular melanoma. *Pigment Cell Melanoma Res.* 2019;32:412–423.
- Nishimura EK. Melanocyte stem cells: a melanocyte reservoir in hair follicles for hair and skin pigmentation. *Pigment Cell Melanoma Res.* 2011;24:401–410.
- Nowacka A, Fajkiel-Madajczyk A, Ohla J, et al. Current treatment of melanoma brain metastases. *Cancers (Basel).* 2023;15:4088.
- Ribas A, Kirkwood JM, Flaherty KT. Anti-PD-1 antibody treatment for melanoma. *Lancet Oncol.* 2018;19:219.
- Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. *N Engl J Med.* 2019;381:626–636.
- Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med.* 2015;372:320–330.
- Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. *N Engl J Med.* 2015;372:2521–2532.
- Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. *Exp Cell Res.* 2001;264:42–55.
- Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. *Lancet Oncol.* 2019;20:948–960.
- Shaikh FY, Gills JJ, Sears CL. Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma. *EBioMedicine.* 2019;48:642–647.
- Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. *N Engl J Med.* 2015;373:1926–1936.
- Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet.* 2017;390:1853–1862.
- Schermers B, Franke V, Rozeman EA, et al. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. *Br J Surg.* 2019;106:519–522.

- Soura E, Eliades PJ, Shannon K, et al. Hereditary melanoma: Update on syndromes and management Genetics of familial atypical multiple mole melanoma syndrome. *J Am Acad Dermatol.* 2016;74:411–420.
- Simonetti O, Goteri G, Lucarini G, et al. Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. *Eur J Cancer.* 2006;42:1181–1187.
- Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. *Nature.* 2012;487:500–504.
- Sullivan RJ, Hamid O, Gonzalez R, et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. *Nat Med.* 2019;25:929–935.
- Sunshine JC, Nguyen PL, Kaunitz GJ, et al. PD-L1 expression in melanoma: A quantitative immunohistochemical antibody comparison. *Clin Cancer Res.* 2017;23:4938–4944.
- Tardelli E, Mazzarri S, Rubello D, et al. Sentinel lymph node biopsy in cutaneous melanoma: standard and new technical procedures and clinical advances. A systematic review of the literature. *Clin Nucl Med.* 2016;41:498–507.
- Uong A, Zon LI. Melanocytes in development and cancer. *J Cell Physiol.* 2010;222:38–41.
- Van Kilsdonk JWJ, Bergers M, Van Kempen LCLT, et al. Keratinocytes drive melanoma invasion in a reconstructed skin model. *Melanoma Res.* 2010;20:372–380.
- Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. *Cancer Res.* 2011;71:7137–7140.
- Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. *J Clin Oncol.* 2011;29:3085–3096.
- Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *N Engl J Med.* 2017;377:1824–1835.
- WHO Classification of Skin Tumours. 4th edition, volume 11. 978-92-832-2440-2.
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med.* 2017;377:1345–1356.

- Xiao D, Barry S, Kmetz D, et al. Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment. *Cancer Lett.* 2016;376:318–327.
- Zhou L, Yang K, Dunaway S, , et al. Suppression of MAPK signaling in BRAF-activated PTEN-deficient melanoma by blocking β -catenin signaling in cancer-associated fibroblasts. *Pigment Cell Melanoma Res.* 2018;31:297–307.
- Zhou L, Yang K, Wickett RR, et al. Targeted deactivation of cancer-associated fibroblasts by β -catenin ablation suppresses melanoma growth. *Tumour Biol.* 2016;37:14235–14248.